Melphalan, Prednisone and Thalidomide

DRUG2 trials

Sponsors

Celgene, Gruppo Italiano Studio Linfomi

Conditions

Multiple Myeloma

Phase 2

A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma

CompletedNCT01274403

Gruppo Italiano Studio LinfomiMultiple Myeloma

Updated: 2011-01-11

Phase 3

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

CompletedNCT00689936

CelgeneMultiple Myeloma

Start: 2008-08-21End: 2016-07-14Updated: 2019-11-20

Related Papers

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.

2023-12-0713 citations

ECOG,β2-Microglobulin, Hemoglobin and Lactate Dehydrogenase Can Predict Early Grade ≥ 3 Infection Accurately in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Study from China

Blood2022-11-15

<i>F</i> railty-adjusted therapy <i>i</i> n <i>T</i> ransplant <i>N</i> on- <i>E</i> ligible patient <i>s</i> with newly diagno <i>s</i> ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

BMJ Open2022-06-0133 citations

PF617 IMPACT OF EARLY VS LATE RELAPSE IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A SUB ANALYSIS OF THE PHASE 3 FIRST TRIAL

HemaSphere2019-06-01

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Blood2017-11-17267 citations

Health-related quality of life over time in transplant-ineligible patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone until progression.

Journal of Clinical Oncology2016-05-20

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

Haematologica2015-12-1138 citations

FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT).

Journal of Clinical Oncology2015-05-204 citations

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

New England Journal of Medicine2014-09-03781 citations